How Should One Treat the Patient with Non-Clear Cell Histology?
Ramaprasad Srinivasan MD, PhD provides a good overview of current treatment options.
Presented at the 2016 GUASCO conference in San Francisco
Ramaprasad Srinivasan MD, PhD provides a good overview of current treatment options.
Presented at the 2016 GUASCO conference in San Francisco
Elizabeth Y. Wei and James J. Hsieh
Elizabeth Y Wei, Ying-Bei Chen, James J Hsieh
Alexander Sankin, A. Ari Hakimi, James J. Hsieh and Ana M. Molina
James Hsieh, MD, PhD
This is the first of a two-part series on reclassification of renal cell carcinomas (RCCs), many of which are con- sidered non-clear cell RCC (nccRCC). The first part will
John R. Srigley, MD, Brett Delahunt, MD, John N. Eble, MD, Lars Egevad, MD, PhD,
Jonathan I. Epstein, MD, David Grignon, MD, Ondrej Hes, MD, PhD, Holger Moch, MD,
Rodolfo Montironi, MD, Satish K. Tickoo, MD, Ming Zhou, MD, PhD,
Pedram Argani, MD, and The ISUP Renal Tumor Panel
W. Marston Linehan, Ramaprasad Srinivasan, and Laura S. Schmidt
This one article was imdependently recommended to me by two different patient advocate organizations: SmartPatient.coms and IKCC.org.
W. Marston Linehan, James Vasselli, Ramaprasad Srinivasan, McClellan M. Walther, Maria Merino, Peter Choyke, Cathy Vocke, Laura Schmidt, Jennifer S. Isaacs, Gladys Glenn, Jorge Toro, Berton Zbar, Donald Bottaro and Len Neckers